Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment

Keyphrases

• Patient Preference 100%
• Frontline Therapy 100%
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia 100%
• Discrete Choice Experiment 100%
• Overall Survival 75%
• Cardiovascular Risk 50%
• Long-term Survival 50%
• Remission 50%
• Treatment Side Effects 50%
• Risk Tolerance 50%
• Older Patients 25%
• Treatment Alternatives 25%
• Leukemia 25%
• High Risk 25%
• Quality of Life 25%
• Potential Gains 25%
• Chemotherapy 25%
• Personal Preferences 25%
• Tyrosine Kinase Inhibitor 25%
• Cardiovascular Effects 25%
• Treatment Decisions 25%
• Survival Benefit 25%
• Overall Risk 25%
• Myelosuppression 25%
• Major Adverse Cardiovascular Events 25%
• Shared Decision Making 25%
• Plain Language Summary 25%

Nursing and Health Professions

• Side Effect 100%
• Patient Preference 100%
• Acute Lymphoblastic Leukemia 100%
• Philadelphia 1 Chromosome 100%
• Overall Survival 75%
• Cardiovascular Risk 50%
• Remission 50%
• Quality of Life 25%
• Leukemia 25%
• Protein Tyrosine Kinase Inhibitor 25%
• Shared Decision-Making 25%
• Bone Marrow Suppression 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Side Effect 100%
• Philadelphia 1 Chromosome 100%
• Acute Lymphoblastic Leukemia 100%
• Overall Survival 75%
• Cardiovascular Risk 50%
• Remission 50%
• Chemotherapy 25%
• Leukemia 25%
• Protein Tyrosine Kinase Inhibitor 25%
• Bone Marrow Suppression 25%